Hologic (HOLX) 10-Q 27 Jan 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Dec. 26, 2015	Jan. 22, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 26, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Entity Registrant Name	HOLOGIC INC
Entity Central Index Key	859,737
Current Fiscal Year End Date	--09-24
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		283,818,060

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Revenues:
Product	$ 587.2	$ 546.6
Service and other	108	106.2
Revenues	695.2	652.8
Costs of revenues:
Product	188.2	186.7
Amortization of intangible assets	73.4	73.9
Service and other	54.5	53.6
Gross Profit	379.1	338.6
Operating expenses:
Research and development	51.7	52
Selling and marketing	99.4	86
General and administrative	77	61.3
Amortization of intangible assets	22.6	27.8
Restructuring and divestiture charges	2.3	8
Operating expenses	253	235.1
Income from operations	126.1	103.5
Interest income	0.2	0.4
Interest expense	(39.2)	(52.5)
Debt extinguishment loss	0	(6.7)
Other income (expense), net	27.6	(0.6)
Income before income taxes	114.7	44.1
Provision for income taxes	29.8	14.9
Net income	$ 84.9	$ 29.2
Net income per common share:
Basic	$ 0.30	$ 0.10
Diluted	$ 0.29	$ 0.10
Weighted average number of shares outstanding:
Basic	282,976	278,671
Diluted	291,971	283,176

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 84.9	$ 29.2
Changes in foreign currency translation adjustment	(4.2)	(9)
Changes in unrealized holding gains and losses on available-for-sale securities:	(0.6)	5.1
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	(7.2)	0
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	0	0.1
Changes in value of hedged interest rate caps, net of tax of $0.2:	0.3	0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax	0.3	0
Other comprehensive loss	(11.4)	(3.8)
Comprehensive income	$ 73.5	$ 25.4

Consolidated Statements of Com4

Consolidated Statements of Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Statement of Comprehensive Income [Abstract]
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax	$ 0.2	$ 0

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 26, 2015	Sep. 26, 2015
Current assets:
Cash and cash equivalents	$ 650.3	$ 491.3
Restricted cash	0	1.4
Accounts receivable, less reserves of $12.2 and $11.1, respectively	410.5	416.1
Inventories	286.4	283.1
Deferred income tax assets	0	19
Prepaid income taxes	0	21.7
Prepaid expenses and other current assets	40.5	33.8
Total current assets	1,387.7	1,266.4
Property, plant and equipment, net	454.5	457.1
Intangible assets, net	2,926.7	3,023.2
Goodwill	2,806.9	2,808.2
Other assets	103.7	115.2
Total assets	7,679.5	7,670.1
Current liabilities:
Current portion of long-term debt	393.3	391.8
Accounts payable	112	117
Accrued expenses	253.2	272.1
Deferred revenue	156.9	163.1
Total current liabilities	915.4	944
Long-term debt, net of current portion	3,239.1	3,248
Deferred income tax liabilities	1,131.6	1,178.4
Deferred revenue	20.3	19.6
Other long-term liabilities	$ 206.8	$ 200.9
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued	$ 0	$ 0
Common stock, $0.01 par value – 750,000 shares authorized; 283,537 and 282,495 shares issued, respectively	2.8	2.8
Additional paid-in-capital	5,573.5	5,559.9
Accumulated deficit	(3,384.1)	(3,469)
Accumulated other comprehensive loss	(25.9)	(14.5)
Total stockholders’ equity	2,166.3	2,079.2
Total liabilities and stockholders’ equity	$ 7,679.5	$ 7,670.1

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Dec. 26, 2015	Sep. 26, 2015
Statement of Financial Position [Abstract]
Accounts receivable, reserves	$ 12.2	$ 11.1
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	1,623,000	1,623,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	750,000,000	750,000,000
Common stock, issued (in shares)	283,537,000	282,495,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
OPERATING ACTIVITIES
Net income	$ 84.9	$ 29.2
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	19.9	20.3
Amortization	96	101.7
Non-cash interest expense	13.2	16.7
Stock-based compensation expense	15.9	12.1
Excess tax benefit related to equity awards	(7.1)	(3)
Deferred income taxes	(28)	(30.5)
Gain (Loss) on Disposition of Intangible Assets	(25.1)	0
Debt extinguishment loss	0	6.7
Loss on disposal of property and equipment	1.3	1.7
Other adjustments and non-cash items	(1.5)	1.2
Changes in operating assets and liabilities:
Accounts receivable	4.3	(9.7)
Inventories	(3.6)	18.7
Prepaid income taxes	21.7	22.4
Prepaid expenses and other assets	(7.7)	(3)
Accounts payable	(4.9)	(24.8)
Accrued expenses and other liabilities	(9.8)	(5)
Deferred revenue	(5.2)	(1.2)
Net cash provided by operating activities	164.3	153.5
INVESTING ACTIVITIES
Purchase of property and equipment	(9.1)	(10.8)
Increase in equipment under customer usage agreements	(10.6)	(10.3)
Proceeds from Sale of Available-for-sale Securities	31.1	0
Purchases of insurance contracts	0	(6.4)
Sales of mutual funds	0	6.4
Increase in other assets	0.9	(0.9)
Net cash provided by (used in) investing activities	12.3	(22)
FINANCING ACTIVITIES
Repayment of long-term debt	(18.8)	(328.8)
Repayments of Convertible Debt	(0.1)	0
Net proceeds from issuance of common stock pursuant to employee stock plans	11.1	15.2
Excess tax benefit related to equity awards	7.1	3
Payment of minimum tax withholdings on net share settlements of equity awards	(14.9)	(10.6)
Net cash used in financing activities	(15.6)	(321.2)
Effect of exchange rate changes on cash and cash equivalents	(2)	(2.4)
Net increase (decrease) in cash and cash equivalents	159	(192.1)
Cash and cash equivalents, beginning of period	491.3	736.1
Cash and cash equivalents, end of period	$ 650.3	$ 544

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 26, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (“SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”). These financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended September 26, 2015 included in the Company’s Form 10-K filed with the SEC on November 19, 2015. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three months ended December 26, 2015 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 24, 2016 . Subsequent Events Consideration The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events recorded in the unaudited consolidated financial statements as of and for the three months ended December 26, 2015 .

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Dec. 26, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis The Company has investments in publicly-traded companies and mutual funds, both of which are valued using quoted market prices, representing Level 1 assets, and investments in derivative instruments comprised of interest rate caps and forward foreign currency contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of the Company's interest rate cap and forward foreign currency contracts represent the estimated amounts the Company would receive to terminate the contracts. Refer to Note 5 for further discussion and information on the interest rate cap and forward foreign currency contracts. The Company has a payment obligation to the participants under its Nonqualified Deferred Compensation Plan (“DCP”). This liability is recorded at fair value based on the underlying value of certain hypothetical investments under the DCP as designated by each participant for their benefit. Since the value of the DCP obligation is based on market prices, the liability is classified within Level 1. Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 26, 2015 : Fair Value at Reporting Date Using Balance as of December 26, 2015 Quoted Prices in Active Market for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Marketable securities: Equity securities $ 1.5 $ 1.5 $ — $ — Mutual funds 5.8 5.8 — — Interest rate cap - derivative 7.3 — 7.3 — Forward foreign currency contracts 1.0 — 1.0 — Total $ 15.6 $ 7.3 $ 8.3 $ — Liabilities: Deferred compensation liabilities $ 38.4 $ 38.4 $ — $ — Total $ 38.4 $ 38.4 $ — $ — Assets Measured and Recorded at Fair Value on a Nonrecurring Basis The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets are comprised of cost-method equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill. The Company holds certain cost-method equity investments in non-publicly traded securities aggregating $4.2 million at both December 26, 2015 and September 26, 2015 , respectively, which are included in other long-term assets on the Company’s Consolidated Balance Sheets. These investments are generally carried at cost, less any write-downs for other-than-temporary impairment charges. To determine the fair value of these investments, the Company uses all available financial information related to the entities, including information based on recent or pending third-party equity investments in these entities. In certain instances, a cost method investment’s fair value is not estimated as there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment and to make such an estimate would be impractical. Disclosure of Fair Value of Financial Instruments The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, marketable securities, cost-method equity investments, interest rate caps, forward foreign currency contracts, insurance contracts, DCP liability, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s marketable securities, interest rate caps, and forward foreign currency contracts are recorded at fair value. The carrying amount of the insurance contracts are recorded at the cash surrender value, as required by U.S. GAAP, which approximates fair value, and the related DCP liability is recorded at fair value. The Company believes the carrying amounts of its cost-method equity investments approximate fair value. Amounts outstanding under the Company’s Credit Agreement of $1.64 billion aggregate principal as of December 26, 2015 are subject to variable rates of interest based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s Senior Notes had a fair value of approximately $1.02 billion as of December 26, 2015 based on their trading price, representing a Level 1 measurement. The fair value of the Company’s Convertible Notes is based on the trading prices of the respective notes and represents a Level 1 measurement. Refer to Note 4 for the carrying amounts of the various components of the Company’s debt. The estimated fair values of the Company’s Convertible Notes at December 26, 2015 were as follows: 2010 Notes $ 249.8 2012 Notes 666.0 2013 Notes 492.1 $ 1,407.9

Restructuring and Divestiture C

Restructuring and Divestiture Charges	3 Months Ended
	Dec. 26, 2015
Restructuring and Related Activities [Abstract]
Restructuring and Divestiture Charges	Restructuring and Divestiture Charges The Company evaluates its operations for opportunities to improve operational effectiveness and efficiency, including facility and operations consolidation, and to better align expenses with revenues. In addition, the Company continually assesses its management structure. As a result of these assessments, the Company has undertaken various restructuring actions, which are described below. The following table displays charges taken in the fiscal 2016 year to date period and fiscal 2015 related to these actions and a rollforward of the accrued balances from September 26, 2015 to December 26, 2015 : Fiscal 2016 Actions Fiscal 2015 Actions Fiscal 2014 Actions Other Operating Cost Reductions Total Restructuring and Divestiture Charges Fiscal 2015 charges: Workforce reductions $ — $ 10.0 $ 6.0 $ 0.3 $ 16.3 Facility closure costs — — 2.0 0.6 2.6 Fiscal 2015 restructuring charges $ — $ 10.0 $ 8.0 $ 0.9 $ 18.9 Divestiture net charges 9.6 Fiscal 2015 restructuring and divestiture charges $ 28.5 Fiscal 2016 charges: Workforce reductions $ 2.3 $ — $ — $ — $ 2.3 Fiscal 2016 restructuring charges $ 2.3 $ — $ — $ — $ 2.3 Fiscal 2016 Actions Fiscal 2015 Actions Fiscal 2014 Actions Other Operating Cost Reductions Total Rollforward of Accrued Restructuring Balance as of September 26, 2015 $ — $ 3.1 $ 2.5 $ 0.1 $ 5.7 Fiscal 2016 restructuring charges 2.3 — — — 2.3 Severance payments (1.2 ) (1.3 ) (1.2 ) (0.1 ) (3.8 ) Other payments — — (0.1 ) — (0.1 ) Balance as of December 26, 2015 $ 1.1 $ 1.8 $ 1.2 $ — $ 4.1 Fiscal 2016 Actions During the third quarter of fiscal 2015, the Company decided to close its Bedford, Massachusetts facility where it manufactures its Skeletal Health products as well as certain support manufacturing services for its Breast Health segment. The manufacturing of the Skeletal Health products will be outsourced to a third-party, and the Breast Health manufacturing services will be moved to the Company's Danbury, Connecticut and Marlborough, Massachusetts facilities. In addition, research and development, sales and services support and administrative functions will be moved to both Marlborough and Danbury. The transition is expected to be completed by the end of fiscal 2016. In connection with this plan, certain employees, primarily in manufacturing, will be terminated. The employees were notified of termination and related benefits in the first quarter of fiscal 2016, and the Company is recording these charges pursuant to ASC 420 Exit or Disposal Cost Obligations (ASC 420). Employees are required to remain employed during this transition period and charges will be recorded ratably over the required service period. The Company recorded $0.5 million in severance and benefits charges in the first quarter of fiscal 2016 related to this plan. The Company estimates the total severance and benefits charges will be approximately $1.7 million . During the first quarter of fiscal 2016, the Company began implementing a second plan to consolidate and improve operational efficiency of its international sales and marketing and field services operations and certain support functions. As a result, the Company terminated certain employees in the first quarter of fiscal 2016. Severance and benefits under this action were recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712), and ASC 420 depending on the circumstances. The Company recorded severance and benefit charges of $1.8 million in the first quarter of fiscal 2016. The Company is continuing to assess its organizational structure and finalize its plans and additional severance charges are expected in fiscal 2016. Fiscal 2015 Actions During each quarter of fiscal 2015, the Company continued to make executive management changes resulting in the termination of certain executives and employees on a worldwide basis. In addition, the Company continued to consolidate and close certain international offices to improve operational efficiency and reduce costs. Severance and benefit charges under these actions were recorded pursuant to ASC 420 and ASC 712 depending on the circumstances, and the Company recorded severance and benefit charges of $10.0 million in fiscal 2015, including $4.1 million of stock-based compensation. During the first quarter of fiscal 2015, the Company recorded $2.5 million for severance and benefits charges. No additional charges are expected under these actions. In connection with its review of operations, the Company decided to shut-down its manufacturing operation in China, which manufactured mammography systems for the Chinese market. As a result, the Company terminated manufacturing and research and development personnel located in China, and the severance charge was insignificant. Fiscal 2014 Actions In each quarter of fiscal 2014, the Company made executive management changes, including appointing Stephen P. MacMillan as President, Chief Executive Officer and a director of the Company, and implemented a number of cost reduction initiatives resulting in the termination of certain executives and employees on a worldwide basis. In addition, in the fourth quarter of fiscal 2014, the Company decided to consolidate and close certain international offices. Severance and benefit charges under these actions were recorded pursuant to ASC 420 and ASC 712 depending on the circumstances. For those employees who continued to be employed beyond the minimum retention period, charges were recorded ratably over the estimated period of the affected employees. During fiscal 2015, in connection with these actions, the Company recorded $6.0 million for severance and benefits costs and $2.0 million for facility closure costs related to this action. The facility closure costs primarily relate to lease obligation charges for three office locations where the Company had met the cease-use date criteria. During the first quarter of fiscal 2015, the Company recorded severance and benefit charges of $2.5 million . This action was completed in fiscal 2015. Divestitures In the fourth quarter of fiscal 2014, the Company completed the sale of its MRI breast coils product line and recorded a loss on disposal of $5.3 million . The Company also provided certain transition services through April 2015, including the manufacturing and sale of inventory to the buyer. Since all operations had ceased during the third quarter of fiscal 2015, the Company concluded that this subsidiary had been substantially liquidated and recorded a $9.6 million charge in the third quarter of fiscal 2015 to write off the cumulative translation adjustment related to the subsidiary.

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	3 Months Ended
	Dec. 26, 2015
Debt Disclosure [Abstract]
Borrowings and Credit Arrangements	Borrowings and Credit Arrangements The Company’s borrowings consisted of the following: December 26, September 26, Current debt obligations, net of debt discount: Term Loan $ 74.7 $ 74.6 Revolver 175.0 175.0 Convertible Notes 143.6 142.2 Total current debt obligations $ 393.3 $ 391.8 Long-term debt obligations, net of debt discount: Term Loan 1,381.4 1,399.8 2022 Senior Notes 987.2 986.7 Convertible Notes 870.5 861.5 Total long-term debt obligations $ 3,239.1 $ 3,248.0 Total debt obligations $ 3,632.4 $ 3,639.8 Credit Agreement Borrowings outstanding under the Credit Agreement and Prior Credit Agreement for the three months ended December 26, 2015 and December 27, 2014 had weighted-average interest rates of 1.95% and 2.77% , respectively. The interest rate on the outstanding Term Loan borrowing at December 26, 2015 was 2.17% . Interest expense under the Credit Agreement aggregated $10.0 million for the three months ended December 26, 2015 , which includes non-cash interest expense of $1.1 million related to the amortization of the deferred issuance costs and accretion of the debt discount. Interest expense under the Prior Credit Agreement aggregated $17.6 million for the three months ended December 27, 2014 , which included $3.1 million of non-cash interest expense related to the amortization of the deferred issuance costs and accretion of the debt discount. The Credit Agreement contains total net leverage ratio and interest coverage ratio financial covenants measured as of the last day of each fiscal quarter. These terms, and the calculation thereof, are defined in further detail in the Credit Agreement. As of December 26, 2015 , the Company was in compliance with these covenants. On December 24, 2014, the Company voluntarily pre-paid $300.0 million of its Term Loan B facility under its Prior Credit Agreement. Pursuant to ASC 470, Debt (ASC 470), the Company recorded a debt extinguishment loss of $6.7 million in the first quarter of fiscal 2015 to write-off the pro-rata amount of unamortized debt discount and deferred issuance costs related to this voluntary prepayment. 2022 Senior Notes The Company's 5.250% Senior Notes due 2022 (the “2022 Senior Notes”) mature on July 15, 2022 and bear interest at the rate of 5.250% per year, payable semi-annually on January 15 and July 15 of each year, commencing on January 15, 2016. The Company recorded interest expense of $14.0 million in the three month period ended December 26, 2015 , which includes non-cash interest expense of $1.0 million related to the amortization of the deferred issuance costs and accretion of the debt discount. The Company used the net proceeds from the 2022 Senior Notes, plus available cash to discharge and redeem all of its outstanding 6.25% Senior Notes due 2020 ("Senior Notes"). The Company recorded interest expense for its Senior Notes of $16.0 million in the three month period ended December 27, 2014 , which included non-cash interest expense of $0.4 million related to the amortization of deferred issuance costs. Convertible Notes During the first quarter of fiscal 2016, the closing price of the Company's common stock exceeded 130% of the applicable conversion price of its 2010 Notes on at least 20 of the last 30 consecutive trading days of the quarter. As a result, holders of 2010 Notes are able to convert their notes during the second quarter of fiscal 2016. As such, the Company classified the $143.6 million carrying value of its 2010 Notes (which have a principal value of $149.9 million ) as a current debt obligation. In the event the closing price conditions are met in the second quarter of fiscal 2016 or a future fiscal quarter, the 2010 Notes will be convertible at a holder's option during the immediately following fiscal quarter. As of December 26, 2015 , the if-converted value of the 2010 Notes exceeded the aggregate principal amount by approximately $99.9 million . It is the Company's current intent and policy to settle any conversion of the Convertible Notes as if the Company had elected to make either a net share settlement or all cash election, such that upon conversion, the Company intends to pay the holders in cash for the principal amount of the 2010 Notes and, if applicable, shares of its common stock or cash to satisfy the premium based on a calculated daily conversion value. Interest expense under the Convertible Notes was as follows: Three Months Ended December 26, December 27, Amortization of debt discount $ 6.4 $ 8.8 Amortization of deferred financing costs 0.3 0.4 Principal accretion 4.1 3.9 Non-cash interest expense 10.8 13.1 2.00% accrued interest (cash) 3.2 4.8 $ 14.0 $ 17.9

Derivatives (Notes)

Derivatives (Notes)	3 Months Ended
	Dec. 26, 2015
Derivatives [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	Derivatives Interest Rate Cap - Cash Flow Hedge The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk by the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in Other income (expense) in the Consolidated Statements of Income. During fiscal 2015, the Company entered into separate interest rate cap agreements with multiple counter-parties to help mitigate the interest rate volatility associated with the variable rate interest on its credit facilities under the Prior Credit Agreement, which has been replaced by the new Credit Agreement. Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid by the Company for the interest rate cap agreements was $13.2 million , which was the initial fair value of the instruments recorded in the Company's financial statements. The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under the Prior Credit Agreement. The terms in the new Credit Agreement are consistent with the Prior Credit Agreement, and therefore the interest rate caps continue to be highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal for a three-year period, which ends on December 29, 2017. As of December 26, 2015 , the Company determined that the existence of hedge ineffectiveness, if any, was immaterial and all changes in the fair value of the interest rate caps are recorded in the Consolidated Statements of Comprehensive Income as a component of AOCI. During the three months ended December 26, 2015 , $0.3 million was reclassified from AOCI to the Company’s Consolidated Statements of Income related to the interest rate cap agreements. The Company expects to similarly reclassify approximately $5.7 million from AOCI to the Consolidated Statements of Income in the next twelve months. The aggregate fair value of these interest rate caps was $7.3 million at December 26, 2015 and is included in both Prepaid expenses and other current assets and Other assets on the Company’s Consolidated Balance Sheet. Refer to Note 2 “Fair Value Measurements” above for related fair value disclosures. Forward Foreign Currency Contracts The Company enters into forward foreign currency exchange contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, and the Australian dollar. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are for periods of one year or less. During the first quarter of fiscal 2016, the Company began to execute forward foreign currency contracts in order to mitigate its exposure to fluctuations in various currencies against its reporting currency, the U.S. dollar. The Company did not elect hedge accounting for these forward foreign currency contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. During the three months ended December 26, 2015 , the Company recorded a net unrealized gain of $1.0 million on the mark-to-market for its outstanding forward foreign currency contracts within other income (expense), net in the Consolidated Statements of Income and a realized gain of $0.4 million from settling forward foreign currency contracts. As of December 26, 2015 , the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Euro, UK Pound and the Australian dollar with a notional amount of $97.7 million . Financial Instrument Presentation The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of December 26, 2015: Balance Sheet Location December 26, 2015 Assets: Derivative instruments designated as a cash flow hedge: Interest rate cap agreements Prepaid expenses and other current assets $ 1.1 Interest rate cap agreements Other assets 6.2 $ 7.3 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 1.0 The following table presents the unrealized gain recognized in AOCI related to the interest rate caps for the following reporting periods: Three Months Ended December 26, 2015 Three Months Ended December 27, 2014 Amount of gain recognized in other comprehensive income, net of taxes: Interest rate cap agreements $ 0.3 $ — The following table presents the adjustment to fair value recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting: Derivatives not classified as hedging instruments Amount of Gain Recognized in Income Location of Gain Recognized in Income (Ineffective Portion) Three Months Ended December 26, 2015 Forward foreign currency contracts $ 1.4 Other income (expense), net

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 26, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation and Related Matters On June 9, 2010, Smith & Nephew, Inc. ("Smith & Nephew") filed suit against Interlace, which the Company acquired on January 6, 2011, in the United States District Court for the District of Massachusetts. The complaint alleged that the Interlace MyoSure hysteroscopic tissue removal device infringed U.S. patent 7,226,459. On November 22, 2011, Smith & Nephew filed suit against the Company in the United States District Court for the District of Massachusetts. The complaint alleged that use of the MyoSure hysteroscopic tissue removal system infringed U.S. patent 8,061,359. Both complaints sought permanent injunctive relief and unspecified damages. On September 4, 2012, following a two week trial, the jury returned a verdict of infringement of both the ‘459 and ‘359 patents and assessed damages of $4.0 million . A bench trial regarding the Company’s assertion of inequitable conduct on the part of Smith & Nephew with regard to the ‘359 patent was held on December 9, 2012 and oral arguments on the issue of inequitable conduct were presented on February 27, 2013. On June 27, 2013, the Court denied the Company’s motions related to inequitable conduct and allowed Smith & Nephew’s request for injunction, but ordered that enforcement of the injunction be stayed until final resolution, including appeal, of the current re-examinations of both patents at the United States Patent and Trademark Office (“USPTO”). The Court also rejected the jury’s damage award and ordered the parties to identify a mechanism for resolving the damages issue. The Company intends to file post-trial motions seeking to reverse the jury’s verdict. The USPTO has issued final decisions that the claims of the ‘459 and the '359 patents asserted as part of the litigation are not patentable. Smith & Nephew has appealed these decisions to the U.S. Patent Trial and Appeal Board. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. In January 2012, Enzo Life Sciences, Inc. ("Enzo") filed suit against the Company's subsidiary, Gen-Probe Incorporated ("Gen-Probe"), in the United States District Court for the District of Delaware. The Gen-Probe complaint alleged that certain of Gen-Probe’s diagnostics products, including products that incorporate Gen-Probe’s patented hybridization protection assay technology, such as the Aptima Combo 2 and Aptima HPV assays, infringe Enzo’s U.S. patent 6,992,180. On March 6, 2012, Enzo filed suit against the Company in the United States District Court for the District of Delaware. The complaint alleged that certain of the Company’s molecular diagnostics products, including without limitation products based on its proprietary Invader chemistry, such as Cervista HPV HR and Cervista HPV 16/18, infringe Enzo’s U.S. patent 6,992,180. The complaint seeks permanent injunctive relief and unspecified damages. On September 30, 2013, Enzo amended its list of accused products to include Prodesse, MilliPROBE, PACE and Procleix assays. The complaint seeks permanent injunctive relief and unspecified damages. Enzo has asserted the ‘180 patent claims against six other companies. The court issued a Markman order on July 7, 2015 construing the claims, and it is expected that summary judgment motions will be heard in the fall of 2016. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. On March 27, 2015, Enzo filed an additional suit against the Company in the United States District Court for the District of Delaware. The complaint alleged that certain additional Company molecular diagnostic products, including, inter alia, the Procleix Parvo/HAV assays and coagulation products, including the Invader Factor II test and the Invader Factor V test, also infringe U.S. Patent 6,992,180. The complaint further alleged that certain of the Company’s molecular diagnostic products, including the Company’s Progensa PCA3 products, all Aptima products and all Procleix products infringe Enzo’s U. S. Patent 7,064,197. On June 11, 2015, this matter was stayed pending the resolution of summary judgment motions in the 2012 case referenced above. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses. The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which would have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies . Legal costs are expensed as incurred.

Marketable Securities

Marketable Securities	3 Months Ended
	Dec. 26, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities The following reconciles the cost basis to the fair market value of the Company’s equity securities that are classified as available-for-sale: Period Ended: Cost Gross Unrealized Gains Gross Unrealized Losses Other Than Temporary Impairment Fair Value December 26, 2015 $ 2.4 $ — $ (0.9 ) $ — $ 1.5 September 26, 2015 $ 16.1 $ 7.2 $ (0.3 ) $ (7.8 ) $ 15.2 In the first quarter of fiscal 2016, the Company sold all of its shares in one of its marketable securities and recorded a realized gain of $25.1 million in Other income (expense), net. In the fourth quarter of fiscal 2015, the Company concluded that the decline in fair value of one of its marketable securities was other-than-temporary based on the length of time the security's market value was significantly below its carrying value and recorded an impairment charge of $7.8 million .

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Dec. 26, 2015
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income Per Share A reconciliation of basic and diluted share amounts is as follows: Three Months Ended December 26, December 27, Basic weighted average common shares outstanding 282,976 278,671 Weighted average common stock equivalents from assumed exercise of stock options and stock units 3,109 2,464 Incremental shares from Convertible Notes premium 5,886 2,041 Diluted weighted average common shares outstanding 291,971 283,176 Weighted-average anti-dilutive shares related to: Outstanding stock options 733 3,782 Stock units 67 140 The Company has outstanding Convertible Notes, and the principal balance and any conversion premium may be satisfied, at the Company’s option, by issuing shares of common stock, cash or a combination of shares and cash. The Company's current policy is that it will settle the principal balance of the Convertible Notes in cash. As such, the Company applies the treasury stock method to these securities and the dilution related to the conversion premium of the 2010, 2012 and 2013 Notes is included in the calculation of diluted weighted-average shares outstanding for fiscal 2016 as the average stock price during the quarter was greater than the conversion price of the 2010, 2012 and 2013 Notes.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Dec. 26, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended December 26, December 27, Cost of revenues $ 2.2 $ 2.0 Research and development 2.4 1.9 Selling and marketing 2.5 2.0 General and administrative 8.8 6.1 Restructuring and divestiture — 0.1 $ 15.9 $ 12.1 The Company granted 0.9 million and 1.0 million stock options during the three months ended December 26, 2015 and December 27, 2014 , respectively, with weighted-average exercise prices of $39.94 and $26.12 , respectively. There were 7.2 million options outstanding at December 26, 2015 with a weighted-average exercise price of $24.50 . The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended December 26, December 27, Risk-free interest rate 1.6 % 1.7 % Expected volatility 37.8 % 38.6 % Expected life (in years) 4.7 5.3 Dividend yield — — Weighted average fair value of options granted $ 13.13 $ 9.44 The Company granted 0.9 million and 1.3 million restricted stock units (RSUs) during the three months ended December 26, 2015 and December 27, 2014 , respectively, with weighted-average grant date fair values of $39.96 and $26.17 , per unit respectively. As of December 26, 2015 , there were 3.5 million unvested RSUs outstanding with a weighted-average grant date fair value of $29.36 per unit. In addition, the Company granted 0.2 million and 0.3 million performance stock units (PSUs) during the three months ended December 26, 2015 and December 27, 2014 , respectively, to members of its senior management team, which have a weighted-average grant date fair value of $39.96 and $26.21 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company is recognizing compensation expense ratably over the required service period based on its estimate of the number of shares that will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company will cumulatively adjust compensation expense in the period that the change in estimate is made. At December 26, 2015 , there was $30.7 million and $104.3 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs and PSUs), respectively, to be recognized over a weighted-average period of 3.5 years and 2.6 years, respectively.

Other Balance Sheet Information

Other Balance Sheet Information	3 Months Ended
	Dec. 26, 2015
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information	Other Balance Sheet Information December 26, September 26, Inventories Raw materials $ 103.1 $ 98.3 Work-in-process 58.7 58.7 Finished goods 124.6 126.1 $ 286.4 $ 283.1 Property, plant and equipment Equipment and software $ 371.4 $ 365.9 Equipment under customer usage agreements 311.1 305.7 Building and improvements 182.5 182.1 Leasehold improvements 58.6 59.2 Land 51.4 51.4 Furniture and fixtures 17.1 17.3 992.1 981.6 Less – accumulated depreciation and amortization (537.6 ) (524.5 ) $ 454.5 $ 457.1

Business Segments and Geographi

Business Segments and Geographic Information	3 Months Ended
	Dec. 26, 2015
Segment Reporting [Abstract]
Business Segments and Geographic Information	Business Segments and Geographic Information The Company has four reportable segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items. Identifiable assets for the four principal operating segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no intersegment revenues during the three months ended December 26, 2015 and December 27, 2014 . Segment information is as follows: Three Months Ended December 26, December 27, Total revenues: Diagnostics $ 310.7 $ 304.1 Breast Health 262.2 242.0 GYN Surgical 98.8 84.4 Skeletal Health 23.5 22.3 $ 695.2 $ 652.8 Income from operations: Diagnostics $ 31.6 $ 28.2 Breast Health 71.6 60.6 GYN Surgical 20.8 13.1 Skeletal Health 2.1 1.6 $ 126.1 $ 103.5 Depreciation and amortization: Diagnostics $ 83.7 $ 88.6 Breast Health 7.3 7.6 GYN Surgical 24.6 25.6 Skeletal Health 0.3 0.2 $ 115.9 $ 122.0 Capital expenditures: Diagnostics $ 11.9 $ 14.8 Breast Health 2.0 2.6 GYN Surgical 3.4 2.0 Skeletal Health 0.1 0.2 Corporate 2.3 1.5 $ 19.7 $ 21.1 December 26, September 26, Identifiable assets: Diagnostics $ 3,979.1 $ 4,055.8 Breast Health 815.3 815.4 GYN Surgical 1,634.3 1,658.1 Skeletal Health 27.3 25.3 Corporate 1,223.5 1,115.5 $ 7,679.5 $ 7,670.1 The Company had no customers with balances greater than 10% of accounts receivable as of December 26, 2015 or September 26, 2015 , or any customer that represented greater than 10% of consolidated revenues during the three months ended December 26, 2015 and December 27, 2014 . The Company operates in the following major geographic areas as noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “All others” designation includes Canada, Latin America and the Middle East. Revenues by geography as a percentage of total revenues were as follows: Three Months Ended December 26, December 27, United States 78.4 % 74.0 % Europe 10.0 % 13.6 % Asia-Pacific 7.9 % 8.7 % All others 3.7 % 3.7 % 100.0 % 100.0 %

Income Taxes

Income Taxes	3 Months Ended
	Dec. 26, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period. The Company’s effective tax rate for the three month period ended December 26, 2015 was 25.9% compared to 33.8% for the corresponding period in the prior year. For the current three month period, the effective tax rate was lower than the statutory tax rate primarily due to increased foreign profits at lower tax rates, the domestic production activities deduction benefit, the retroactively reinstated Federal research credit, and a change in the valuation allowance related to the sale of a marketable security that had a gain for book purposes. For the three month period ended December 27, 2014 , the effective tax rate differed from the statutory rate primarily due to the domestic production activities deduction. In November 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) No. 2015-17, Balance Sheet Classification of Deferred Taxes . ASU 2015-17 simplifies the presentation of deferred income taxes by eliminating the requirement for entities to separate deferred income tax liabilities and assets into current and noncurrent amounts in the balance sheet. Rather, it requires that deferred tax assets and liabilities are classified as noncurrent in the balance sheet. The Company adopted this standard prospectively for the three month period ended December 26, 2015 and prior periods were not retrospectively adjusted.

Intangible Assets

Intangible Assets	3 Months Ended
	Dec. 26, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets consisted of the following: Description As of December 26, 2015 As of September 26, 2015 Gross Carrying Value Accumulated Amortization Gross Carrying Value Accumulated Amortization Developed technology $ 3,979.0 $ 1,771.8 $ 3,979.1 $ 1,698.5 In-process research and development 3.7 — 3.7 — Customer relationships and contracts 1,100.3 487.2 1,101.1 467.5 Trade names 236.3 134.0 236.4 131.5 Business licenses 2.5 2.1 2.5 2.1 $ 5,321.8 $ 2,395.1 $ 5,322.8 $ 2,299.6 The estimated remaining amortization expense as of December 26, 2015 for each of the five succeeding fiscal years is as follows: Remainder of Fiscal 2016 $ 280.7 Fiscal 2017 $ 365.2 Fiscal 2018 $ 354.7 Fiscal 2019 $ 343.0 Fiscal 2020 $ 332.0

Product Warranties

Product Warranties	3 Months Ended
	Dec. 26, 2015
Guarantees [Abstract]
Product Warranties	Product Warranties Product warranty activity was as follows: Balance at Beginning of Period Provisions Settlements/ Adjustments Balance at End of Period Three Months Ended: December 26, 2015 $ 5.4 $ 5.7 $ (1.7 ) $ 9.4 December 27, 2014 $ 6.3 $ 1.5 $ (1.8 ) $ 6.0 During the first quarter of fiscal 2016, the Company recorded a warranty provision of $4.0 million related to certain products sold exclusively in the Chinese market.

Accumuated Other Comprehensive

Accumuated Other Comprehensive Income (Notes)	3 Months Ended
	Dec. 26, 2015
Accumulated Other Comprehensive Income [Abstract]
Comprehensive Income (Loss) Note [Text Block]	(15) Accumulated Other Comprehensive Income The following tables summarize the changes in accumulated balances of other comprehensive income for the periods presented: Three Months Ended December 26, 2015 Foreign Currency Translation Marketable Securities Pension Plans Hedged Interest Rate Caps Total Beginning Balance $ (15.7 ) $ 6.9 $ (1.8 ) $ (3.9 ) $ (14.5 ) Other comprehensive income (loss) before reclassifications (4.2 ) (0.6 ) — 0.3 (4.5 ) Amounts reclassified to statement of income — (7.2 ) — 0.3 (6.9 ) Ending Balance $ (19.9 ) $ (0.9 ) $ (1.8 ) $ (3.3 ) $ (25.9 ) Three Months Ended December 27, 2014 Foreign Currency Translation Marketable Securities Pension Plans Total Beginning Balance $ (4.7 ) $ 8.9 $ (1.6 ) $ 2.6 Other comprehensive income (loss) before reclassifications (9.0 ) 5.1 0.1 (3.8 ) Amounts reclassified to statement of income — — — — Ending Balance $ (13.7 ) $ 14.0 $ (1.5 ) $ (1.2 )

New Accounting Pronouncements

New Accounting Pronouncements	3 Months Ended
	Dec. 26, 2015
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements In January 2016, the Financial Accounting Standards Board (FASB) issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities . This guidance changes how entities measure equity investments that do not result in consolidation and are not accounted for under the equity method. Entities will be required to measure these investments at fair value at the end of each reporting period and recognize changes in fair value in net income. A practicability exception will be available for equity investments that do not have readily determinable fair values, however; the exception requires the Company to consider relevant transactions that can be reasonably known to identify any observable price changes that would impact the fair value . This guidance also changes certain disclosure requirements and other aspects of current US GAAP. This guidance is effective for annual periods beginning after December 15, 2017, and is applicable to the Company in fiscal 2019 . Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-01 on its consolidated financial position and results of operations. In July 2015, the FASB issued guidance under ASC 330, Simplifying the Measurement of Inventory. The new guidance requires inventory to be measured at the lower of cost and net realizable value, which is defined as the estimated selling price in the ordinary course of business less reasonably predictable costs of completion, disposal and transportation. This new guidance is effective for the Company's first quarter of fiscal 2018 and early adoption is permitted. The guidance must be applied prospectively. The Company is currently evaluating the impact of the adoption of this requirement on its consolidated financial statements but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements. In April 2015, the FASB issued ASU No. 2015-03, Presentation of Debt Issuance Costs . This guidance intends to simplify the presentation of debt issuance costs and more closely align the presentation of debt issuance costs under U.S. GAAP to IFRS standards. This guidance is effective for annual periods beginning after December 15, 2015, and is applicable to the Company in fiscal 2017. Early adoption is permitted. The Company is currently evaluating this guidance, but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements. In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis . This guidance focuses on a reporting company’s consolidation evaluation to determine whether certain legal entities should be consolidated. This guidance is effective for annual periods beginning after December 15, 2015, and is applicable to the Company in fiscal 2017. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating this guidance, but does not anticipate that adoption of this guidance will have a material impact on its consolidated financial statements. In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate, at each annual or interim reporting period, whether there are conditions or events that exist that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date the financial statements are issued and provide related disclosures. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and is applicable to the Company in fiscal 2018. Early adoption is permitted. The adoption of ASU 2014-15 is not expected to have a material effect on the Company's consolidated financial statements or disclosures. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 660) , which provides guidance for revenue recognition. This ASU is applicable to any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. ASU 2014-09 will supersede the revenue recognition requirements in Topic 605, Revenue Recognition , and most industry-specific guidance. The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to receive in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current U.S. GAAP. These judgments may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. On July 9, 2015, the FASB voted in favor of delaying the effective date of the new standard by one year, with early adoption permitted as of the original effective date. ASU 2014-09 is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2017, which is fiscal 2019 for the Company. The Company is currently evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial position and results of operations.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Dec. 26, 2015
Fair Value Disclosures [Abstract]
Fair Value Assets and Liabilities Measured on Recurring Basis	Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at December 26, 2015 : Fair Value at Reporting Date Using Balance as of December 26, 2015 Quoted Prices in Active Market for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Marketable securities: Equity securities $ 1.5 $ 1.5 $ — $ — Mutual funds 5.8 5.8 — — Interest rate cap - derivative 7.3 — 7.3 — Forward foreign currency contracts 1.0 — 1.0 — Total $ 15.6 $ 7.3 $ 8.3 $ — Liabilities: Deferred compensation liabilities $ 38.4 $ 38.4 $ — $ — Total $ 38.4 $ 38.4 $ — $ —
Estimated Fair Values of Convertible Notes	The estimated fair values of the Company’s Convertible Notes at December 26, 2015 were as follows: 2010 Notes $ 249.8 2012 Notes 666.0 2013 Notes 492.1 $ 1,407.9

Restructuring and Divestiture25

Restructuring and Divestiture Charges (Tables)	3 Months Ended
	Dec. 26, 2015
Restructuring and Related Activities [Abstract]
Charges Taken Related to Restructuring Actions	The following table displays charges taken in the fiscal 2016 year to date period and fiscal 2015 related to these actions and a rollforward of the accrued balances from September 26, 2015 to December 26, 2015 : Fiscal 2016 Actions Fiscal 2015 Actions Fiscal 2014 Actions Other Operating Cost Reductions Total Restructuring and Divestiture Charges Fiscal 2015 charges: Workforce reductions $ — $ 10.0 $ 6.0 $ 0.3 $ 16.3 Facility closure costs — — 2.0 0.6 2.6 Fiscal 2015 restructuring charges $ — $ 10.0 $ 8.0 $ 0.9 $ 18.9 Divestiture net charges 9.6 Fiscal 2015 restructuring and divestiture charges $ 28.5 Fiscal 2016 charges: Workforce reductions $ 2.3 $ — $ — $ — $ 2.3 Fiscal 2016 restructuring charges $ 2.3 $ — $ — $ — $ 2.3
Charges Taken Related to Accrued Restructuring Actions	Fiscal 2016 Actions Fiscal 2015 Actions Fiscal 2014 Actions Other Operating Cost Reductions Total Rollforward of Accrued Restructuring Balance as of September 26, 2015 $ — $ 3.1 $ 2.5 $ 0.1 $ 5.7 Fiscal 2016 restructuring charges 2.3 — — — 2.3 Severance payments (1.2 ) (1.3 ) (1.2 ) (0.1 ) (3.8 ) Other payments — — (0.1 ) — (0.1 ) Balance as of December 26, 2015 $ 1.1 $ 1.8 $ 1.2 $ — $ 4.1

Borrowings and Credit Arrange26

Borrowings and Credit Arrangements (Tables)	3 Months Ended
	Dec. 26, 2015
Debt Disclosure [Abstract]
Company's Borrowings	The Company’s borrowings consisted of the following: December 26, September 26, Current debt obligations, net of debt discount: Term Loan $ 74.7 $ 74.6 Revolver 175.0 175.0 Convertible Notes 143.6 142.2 Total current debt obligations $ 393.3 $ 391.8 Long-term debt obligations, net of debt discount: Term Loan 1,381.4 1,399.8 2022 Senior Notes 987.2 986.7 Convertible Notes 870.5 861.5 Total long-term debt obligations $ 3,239.1 $ 3,248.0 Total debt obligations $ 3,632.4 $ 3,639.8
Interest Expense under Convertible Notes	Interest expense under the Convertible Notes was as follows: Three Months Ended December 26, December 27, Amortization of debt discount $ 6.4 $ 8.8 Amortization of deferred financing costs 0.3 0.4 Principal accretion 4.1 3.9 Non-cash interest expense 10.8 13.1 2.00% accrued interest (cash) 3.2 4.8 $ 14.0 $ 17.9

Derivatives Schedule of Derivat

Derivatives Schedule of Derivative Assets at Fair Value (Tables)	3 Months Ended
	Dec. 26, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Assets at Fair Value [Table Text Block]	Balance Sheet Location December 26, 2015 Assets: Derivative instruments designated as a cash flow hedge: Interest rate cap agreements Prepaid expenses and other current assets $ 1.1 Interest rate cap agreements Other assets 6.2 $ 7.3 Derivatives not designated as hedging instruments: Forward foreign currency contracts Prepaid expenses and other current assets $ 1.0
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The following table presents the unrealized gain recognized in AOCI related to the interest rate caps for the following reporting periods: Three Months Ended December 26, 2015 Three Months Ended December 27, 2014 Amount of gain recognized in other comprehensive income, net of taxes: Interest rate cap agreements $ 0.3 $ —
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	The following table presents the adjustment to fair value recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting: Derivatives not classified as hedging instruments Amount of Gain Recognized in Income Location of Gain Recognized in Income (Ineffective Portion) Three Months Ended December 26, 2015 Forward foreign currency contracts $ 1.4 Other income (expense), net

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Dec. 26, 2015
Investments, Debt and Equity Securities [Abstract]
Reconciles Cost Basis to Fair Market Value of Company's Equity Security	The following reconciles the cost basis to the fair market value of the Company’s equity securities that are classified as available-for-sale: Period Ended: Cost Gross Unrealized Gains Gross Unrealized Losses Other Than Temporary Impairment Fair Value December 26, 2015 $ 2.4 $ — $ (0.9 ) $ — $ 1.5 September 26, 2015 $ 16.1 $ 7.2 $ (0.3 ) $ (7.8 ) $ 15.2

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Dec. 26, 2015
Earnings Per Share [Abstract]
Reconciliation of Basic and Diluted Share Amounts	A reconciliation of basic and diluted share amounts is as follows: Three Months Ended December 26, December 27, Basic weighted average common shares outstanding 282,976 278,671 Weighted average common stock equivalents from assumed exercise of stock options and stock units 3,109 2,464 Incremental shares from Convertible Notes premium 5,886 2,041 Diluted weighted average common shares outstanding 291,971 283,176 Weighted-average anti-dilutive shares related to: Outstanding stock options 733 3,782 Stock units 67 140

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Dec. 26, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation Expense in Consolidated Statements of Operations	The following presents stock-based compensation expense in the Company’s Consolidated Statements of Income: Three Months Ended December 26, December 27, Cost of revenues $ 2.2 $ 2.0 Research and development 2.4 1.9 Selling and marketing 2.5 2.0 General and administrative 8.8 6.1 Restructuring and divestiture — 0.1 $ 15.9 $ 12.1
Weighted-Average Assumptions Utilized to Value Stock Options	The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table: Three Months Ended December 26, December 27, Risk-free interest rate 1.6 % 1.7 % Expected volatility 37.8 % 38.6 % Expected life (in years) 4.7 5.3 Dividend yield — — Weighted average fair value of options granted $ 13.13 $ 9.44

Other Balance Sheet Informati31

Other Balance Sheet Information (Tables)	3 Months Ended
	Dec. 26, 2015
Balance Sheet Related Disclosures [Abstract]
Other Balance Sheet Information of Inventories	December 26, September 26, Inventories Raw materials $ 103.1 $ 98.3 Work-in-process 58.7 58.7 Finished goods 124.6 126.1 $ 286.4 $ 283.1
Other Balance Sheet Information of Property, Plant and Equipment	Property, plant and equipment Equipment and software $ 371.4 $ 365.9 Equipment under customer usage agreements 311.1 305.7 Building and improvements 182.5 182.1 Leasehold improvements 58.6 59.2 Land 51.4 51.4 Furniture and fixtures 17.1 17.3 992.1 981.6 Less – accumulated depreciation and amortization (537.6 ) (524.5 ) $ 454.5 $ 457.1

Business Segments and Geograp32

Business Segments and Geographic Information (Tables)	3 Months Ended
	Dec. 26, 2015
Segment Reporting [Abstract]
Segment Information	Segment information is as follows: Three Months Ended December 26, December 27, Total revenues: Diagnostics $ 310.7 $ 304.1 Breast Health 262.2 242.0 GYN Surgical 98.8 84.4 Skeletal Health 23.5 22.3 $ 695.2 $ 652.8 Income from operations: Diagnostics $ 31.6 $ 28.2 Breast Health 71.6 60.6 GYN Surgical 20.8 13.1 Skeletal Health 2.1 1.6 $ 126.1 $ 103.5 Depreciation and amortization: Diagnostics $ 83.7 $ 88.6 Breast Health 7.3 7.6 GYN Surgical 24.6 25.6 Skeletal Health 0.3 0.2 $ 115.9 $ 122.0 Capital expenditures: Diagnostics $ 11.9 $ 14.8 Breast Health 2.0 2.6 GYN Surgical 3.4 2.0 Skeletal Health 0.1 0.2 Corporate 2.3 1.5 $ 19.7 $ 21.1 December 26, September 26, Identifiable assets: Diagnostics $ 3,979.1 $ 4,055.8 Breast Health 815.3 815.4 GYN Surgical 1,634.3 1,658.1 Skeletal Health 27.3 25.3 Corporate 1,223.5 1,115.5 $ 7,679.5 $ 7,670.1
Revenues by Geography	Revenues by geography as a percentage of total revenues were as follows: Three Months Ended December 26, December 27, United States 78.4 % 74.0 % Europe 10.0 % 13.6 % Asia-Pacific 7.9 % 8.7 % All others 3.7 % 3.7 % 100.0 % 100.0 %

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Dec. 26, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consisted of the following: Description As of December 26, 2015 As of September 26, 2015 Gross Carrying Value Accumulated Amortization Gross Carrying Value Accumulated Amortization Developed technology $ 3,979.0 $ 1,771.8 $ 3,979.1 $ 1,698.5 In-process research and development 3.7 — 3.7 — Customer relationships and contracts 1,100.3 487.2 1,101.1 467.5 Trade names 236.3 134.0 236.4 131.5 Business licenses 2.5 2.1 2.5 2.1 $ 5,321.8 $ 2,395.1 $ 5,322.8 $ 2,299.6
Schedule of Estimated Amortization Expense	The estimated remaining amortization expense as of December 26, 2015 for each of the five succeeding fiscal years is as follows: Remainder of Fiscal 2016 $ 280.7 Fiscal 2017 $ 365.2 Fiscal 2018 $ 354.7 Fiscal 2019 $ 343.0 Fiscal 2020 $ 332.0

Product Warranties (Tables)

Product Warranties (Tables)	3 Months Ended
	Dec. 26, 2015
Guarantees [Abstract]
Product Warranty	Product warranty activity was as follows: Balance at Beginning of Period Provisions Settlements/ Adjustments Balance at End of Period Three Months Ended: December 26, 2015 $ 5.4 $ 5.7 $ (1.7 ) $ 9.4 December 27, 2014 $ 6.3 $ 1.5 $ (1.8 ) $ 6.0

Accumuated Other Comprehensiv35

Accumuated Other Comprehensive Income Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Dec. 26, 2015
Accumulated Other Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	The following tables summarize the changes in accumulated balances of other comprehensive income for the periods presented: Three Months Ended December 26, 2015 Foreign Currency Translation Marketable Securities Pension Plans Hedged Interest Rate Caps Total Beginning Balance $ (15.7 ) $ 6.9 $ (1.8 ) $ (3.9 ) $ (14.5 ) Other comprehensive income (loss) before reclassifications (4.2 ) (0.6 ) — 0.3 (4.5 ) Amounts reclassified to statement of income — (7.2 ) — 0.3 (6.9 ) Ending Balance $ (19.9 ) $ (0.9 ) $ (1.8 ) $ (3.3 ) $ (25.9 ) Three Months Ended December 27, 2014 Foreign Currency Translation Marketable Securities Pension Plans Total Beginning Balance $ (4.7 ) $ 8.9 $ (1.6 ) $ 2.6 Other comprehensive income (loss) before reclassifications (9.0 ) 5.1 0.1 (3.8 ) Amounts reclassified to statement of income — — — — Ending Balance $ (13.7 ) $ 14.0 $ (1.5 ) $ (1.2 )

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) $ in Millions	Dec. 26, 2015USD ($)
Assets:
Assets measured at fair value on a recurring basis	$ 15.6
Interest Rate Cash Flow Hedge Asset at Fair Value	7.3
Liabilities:
Liabilities measured at fair value on a recurring basis	38.4
Equity securities
Assets:
Assets measured at fair value on a recurring basis	1.5
Mutual funds
Assets:
Assets measured at fair value on a recurring basis	5.8
Foreign Exchange Contract [Member]
Assets:
Foreign Currency Contract, Asset, Fair Value Disclosure	1
Deferred compensation liabilities
Liabilities:
Liabilities measured at fair value on a recurring basis	38.4
Quoted Prices in Active Market for Identical Assets (Level 1)
Assets:
Assets measured at fair value on a recurring basis	7.3
Liabilities:
Liabilities measured at fair value on a recurring basis	38.4
Quoted Prices in Active Market for Identical Assets (Level 1) | Equity securities
Assets:
Assets measured at fair value on a recurring basis	1.5
Quoted Prices in Active Market for Identical Assets (Level 1) | Mutual funds
Assets:
Assets measured at fair value on a recurring basis	5.8
Quoted Prices in Active Market for Identical Assets (Level 1) | Interest rate cap - derivative
Assets:
Assets measured at fair value on a recurring basis	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Foreign Exchange Contract [Member]
Assets:
Assets measured at fair value on a recurring basis	0
Quoted Prices in Active Market for Identical Assets (Level 1) | Deferred compensation liabilities
Liabilities:
Liabilities measured at fair value on a recurring basis	38.4
Significant Other Observable Inputs (Level 2)
Assets:
Assets measured at fair value on a recurring basis	8.3
Liabilities:
Liabilities measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) | Equity securities
Assets:
Assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) | Mutual funds
Assets:
Assets measured at fair value on a recurring basis	0
Significant Other Observable Inputs (Level 2) | Interest rate cap - derivative
Assets:
Assets measured at fair value on a recurring basis	7.3
Significant Other Observable Inputs (Level 2) | Foreign Exchange Contract [Member]
Assets:
Assets measured at fair value on a recurring basis	1
Significant Other Observable Inputs (Level 2) | Deferred compensation liabilities
Liabilities:
Liabilities measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3)
Assets:
Assets measured at fair value on a recurring basis	0
Liabilities:
Liabilities measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Equity securities
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Mutual funds
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Interest rate cap - derivative
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Foreign Exchange Contract [Member]
Assets:
Assets measured at fair value on a recurring basis	0
Significant Unobservable Inputs (Level 3) | Deferred compensation liabilities
Liabilities:
Liabilities measured at fair value on a recurring basis	$ 0

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Dec. 26, 2015	Sep. 26, 2015
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Cost Method Investments	$ 4.2	$ 0
Borrowed principal under credit agreement	1,000
Credit Agreement
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Borrowed principal under credit agreement	1,640
Senior Notes
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]
Fair value of debt instrument	$ 1,020

Fair Value Measurements - Estim

Fair Value Measurements - Estimated Fair Values of Convertible Notes (Detail) $ in Millions	Dec. 26, 2015USD ($)
Estimated Fair Value Of Financial Instruments [Line Items]
Estimated fair values of debt instruments	$ 1,407.9
2010 Notes
Estimated Fair Value Of Financial Instruments [Line Items]
Estimated fair values of debt instruments	249.8
2012 Notes
Estimated Fair Value Of Financial Instruments [Line Items]
Estimated fair values of debt instruments	666
2013 Notes
Estimated Fair Value Of Financial Instruments [Line Items]
Estimated fair values of debt instruments	$ 492.1

Restructuring and Divestiture39

Restructuring and Divestiture Charges - Charges Taken Related to Restructuring Actions (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Sep. 26, 2015
Restructuring Cost and Reserve [Line Items]
Fiscal restructuring and divestiture charges	$ 2.3	$ 8
Restructuring | Two Thousand Fifteen [Member]
Restructuring Cost and Reserve [Line Items]
Workforce reductions			$ 16.3
Facility closure costs			2.6
Fiscal restructuring charges			18.9
Divestiture net charges			9.6
Fiscal restructuring and divestiture charges			28.5
Restructuring | Year Two Thousand Sixteen [Domain]
Restructuring Cost and Reserve [Line Items]
Workforce reductions	2.3
Fiscal restructuring charges	2.3
Restructuring | Fiscal 2016 Actions [Domain] | Two Thousand Fifteen [Member]
Restructuring Cost and Reserve [Line Items]
Workforce reductions			0
Facility closure costs			0
Fiscal restructuring charges			0
Restructuring | Fiscal 2016 Actions [Domain] | Year Two Thousand Sixteen [Domain]
Restructuring Cost and Reserve [Line Items]
Workforce reductions	2.3
Fiscal restructuring charges	2.3
Restructuring | Fiscal 2015 Actions | Two Thousand Fifteen [Member]
Restructuring Cost and Reserve [Line Items]
Workforce reductions			10
Facility closure costs			0
Fiscal restructuring charges			10
Restructuring | Fiscal 2015 Actions | Year Two Thousand Sixteen [Domain]
Restructuring Cost and Reserve [Line Items]
Workforce reductions	0
Fiscal restructuring charges	0
Restructuring | Fiscal 2014 Actions | Two Thousand Fifteen [Member]
Restructuring Cost and Reserve [Line Items]
Workforce reductions			6
Facility closure costs			2
Fiscal restructuring charges			8
Restructuring | Fiscal 2014 Actions | Year Two Thousand Sixteen [Domain]
Restructuring Cost and Reserve [Line Items]
Workforce reductions	0
Fiscal restructuring charges	0
Restructuring | Other Operating Cost Reductions | Two Thousand Fifteen [Member]
Restructuring Cost and Reserve [Line Items]
Workforce reductions			0.3
Facility closure costs			0.6
Fiscal restructuring charges			$ 0.9
Restructuring | Other Operating Cost Reductions | Year Two Thousand Sixteen [Domain]
Restructuring Cost and Reserve [Line Items]
Workforce reductions	0
Fiscal restructuring charges	$ 0

Restructuring and Divestiture40

Restructuring and Divestiture Charges - Charges Taken Related to Accrued Restructuring Actions (Detail) - Restructuring - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 26, 2015	Sep. 26, 2015
Two Thousand Fifteen
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan		$ 18.9
Restructuring Reserve [Roll Forward]
Period beginning balance	$ (5.7)
Period end balance		(5.7)
Two Thousand Fifteen | Restructuring Action Two Thousand Sixteen [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan		0
Restructuring Reserve [Roll Forward]
Period beginning balance	0
Period end balance		0
Two Thousand Fifteen | Fiscal 2015 Actions
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan		10
Restructuring Reserve [Roll Forward]
Period beginning balance	(3.1)
Period end balance		(3.1)
Two Thousand Fifteen | Fiscal 2014 Actions
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan		8
Restructuring Reserve [Roll Forward]
Period beginning balance	(2.5)
Period end balance		(2.5)
Two Thousand Fifteen | Other Operating Cost Reductions
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan		0.9
Restructuring Reserve [Roll Forward]
Period beginning balance	(0.1)
Period end balance		$ (0.1)
Two Thousand Sixteen [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan	2.3
Restructuring Reserve [Roll Forward]
Severance payments	(3.8)
Other payments	(0.1)
Period end balance	4.1
Two Thousand Sixteen [Member] | Restructuring Action Two Thousand Sixteen [Domain]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan	2.3
Restructuring Reserve [Roll Forward]
Severance payments	1.2
Other payments	0
Period end balance	(1.1)
Two Thousand Sixteen [Member] | Fiscal 2015 Actions
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan	0
Restructuring Reserve [Roll Forward]
Severance payments	(1.3)
Other payments	0
Period end balance	1.8
Two Thousand Sixteen [Member] | Fiscal 2014 Actions
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan	0
Restructuring Reserve [Roll Forward]
Severance payments	1.2
Other payments	0.1
Period end balance	(1.2)
Two Thousand Sixteen [Member] | Other Operating Cost Reductions
Restructuring Cost and Reserve [Line Items]
Restructuring Charges Under Exit Or Disposal Plan	0
Restructuring Reserve [Roll Forward]
Severance payments	(0.1)
Other payments	0
Period end balance	$ 0

Restructuring and Divestiture41

Restructuring and Divestiture Charges - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended				12 Months Ended
	Dec. 26, 2015	Jun. 27, 2015	Dec. 27, 2014	Sep. 27, 2014	Sep. 26, 2015
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$ 1.7
Loss on disposal of business				$ 5.3
Restructuring Reserve, Translation and Other Adjustment		$ 9.6
Restructuring | Bedford [Member]
Restructuring Cost and Reserve [Line Items]
Severance charges	0.5
Restructuring | International [Member]
Restructuring Cost and Reserve [Line Items]
Severance charges	$ 1.8
Restructuring | Fiscal 2015 charges:
Restructuring Cost and Reserve [Line Items]
Severance charges			$ 2.5		$ 10
Share Based Compensation Expense Included Other Restructuring Costs					4.1
Restructuring | Fiscal 2014 Charges [Member]
Restructuring Cost and Reserve [Line Items]
Severance charges			$ 2.5		6
Facility closure costs					$ 2
Number Office Locations related to Facility Closure Costs					0

Borrowings and Credit Arrange42

Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($) $ in Millions	Dec. 26, 2015	Sep. 26, 2015
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	$ 393.3	$ 391.8
Convertible Notes Payable, Current	143.6	142.2
Convertible Notes	870.5	861.5
Total long-term debt obligations	3,239.1	3,248
Total debt obligations	3,632.4	3,639.8
Term Loan [Member]
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	74.7	74.6
Long-term debt obligations, net of debt discount	1,381.4	1,399.8
Revolver [Member]
Debt Instrument [Line Items]
Current debt obligations, net of debt discount	175	175
2022 Notes [Member]
Debt Instrument [Line Items]
Long-term debt obligations, net of debt discount	$ 987.2	$ 986.7

Borrowings and Credit Arrange43

Borrowings and Credit Arrangements - Interest Expense under Convertible Notes (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Debt Conversion [Line Items]
Non-cash interest expense	$ 13.2	$ 16.7
Convertible Notes Payable
Debt Conversion [Line Items]
Amortization of debt discount	6.4	8.8
Amortization of deferred financing costs	0.3	0.4
Principal accretion	4.1	3.9
Non-cash interest expense	10.8	13.1
2.00% accrued interest (cash)	$ 3.2	$ 4.8
Convertible Notes Interest Expense	2.00%	2.00%
Interest expense, net	$ 14	$ 17.9

Borrowings and Credit Arrange44

Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($)	Dec. 24, 2014	Dec. 26, 2015	Dec. 27, 2014	Jul. 01, 2015	Sep. 26, 2015
Debt Instrument [Line Items]
Non-cash interest expense amortization of debt discount and deferred financing costs		$ 13,200,000	$ 16,700,000
Debt extinguishment loss		0	$ 6,700,000
Convertible Notes Payable, Current		$ 143,600,000			$ 142,200,000
Credit Agreement
Debt Instrument [Line Items]
Weighted average interest rates, Borrowings outstanding under the credit agreement		1.95%	2.77%
Interest expense		$ 10,000,000	$ 17,600,000
Non-cash interest expense amortization of debt discount and deferred financing costs		$ 1,100,000	3,100,000
Term Loan [Member]
Debt Instrument [Line Items]
Weighted average interest rates, Borrowings outstanding under the credit agreement		2.17%
2022 Notes [Member]
Debt Instrument [Line Items]
Interest expense		$ 14,000,000
Non-cash interest expense amortization of debt discount and deferred financing costs		$ 1,000,000
Senior note interest rate per year		5.25%
Senior Notes
Debt Instrument [Line Items]
Interest expense			16,000,000
Non-cash interest expense amortization of debt discount and deferred financing costs			400,000
Senior note interest rate per year				6.25%
Two Thousand Ten Original Notes [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Exceeds Percentage Of Conversion Price Of Common Stock		130.00%
Convertible Notes Payable, Current		$ 143,600,000
Debt Instrument, Face Amount		149,900,000
Amount by which the if-converted value exceeds the principal amount		$ 99,900,000
Term Loan B [Member] | Credit Agreement
Debt Instrument [Line Items]
Prepaid principal amount	$ 300,000,000
Debt extinguishment loss			$ (6,700,000)

Derivatives Fair Value of Deriv

Derivatives Fair Value of Derivative Financial Instruments (Details) $ in Millions	Dec. 26, 2015USD ($)
Interest rate cap - derivative
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 7.3
Interest rate cap - derivative | Prepaid Expenses and Other Current Assets [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	1.1
Interest rate cap - derivative | Other Assets [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	6.2
Foreign Exchange Forward [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Cash Flow Hedge Derivative Instrument Assets at Fair Value	$ 1

Derivatives Schedule of Cash Fl

Derivatives Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Changes in value of hedged interest rate caps, net of tax of $0.2:	$ 0.3	$ 0
Interest rate cap - derivative
Derivative Instruments, Gain (Loss) [Line Items]
Changes in value of hedged interest rate caps, net of tax of $0.2:		$ 0

Derivatives Gain (Loss) on Fair

Derivatives Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details) $ in Millions	3 Months Ended
	Dec. 26, 2015USD ($)
Foreign Exchange Forward [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) on Fair Value Hedges Recognized in Earnings	$ 1.4

Derivatives Additional Informat

Derivatives Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Interest Rate Cap Agreements Aggregate Premium Payable		$ 13.2
Principal Amount Of Borrowings	$ 1,000
Interest Payment Duration	three-year
Changes in value of hedged interest rate caps, net of tax of $0.2:	$ 0.3	$ 0
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	5.7
Interest Rate Cash Flow Hedge Asset at Fair Value	7.3
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax	1
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	0.4
Notional Amount	$ 97.7

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	Sep. 04, 2012USD ($)
Commitments and Contingencies Disclosure [Abstract]
Assessed damages	$ 4

Marketable Securities - Reconci

Marketable Securities - Reconciles Cost Basis to Fair Market Value of Company's Equity Security (Detail) - Equity securities - USD ($) $ in Millions	Dec. 26, 2015	Sep. 26, 2015
Schedule Of Marketable Securities [Line Items]
Available-for-sale Equity Securities, Amortized Cost Basis	$ 2.4	$ 16.1
Gross Unrealized Gains	0	7.2
Gross Unrealized Losses	(0.9)	(0.3)
Other than temporary impairment	0	7.8
Fair Value	$ 1.5	$ 15.2

Marketable Securities Additiona

Marketable Securities Additional Information (Details) - Equity securities - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Sep. 26, 2015
Schedule of Available-for-sale Securities [Line Items]
Realized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments	$ (25.1)
Other than temporary impairment	$ 0	$ 7.8

Net Income (Loss) Per Share - R

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares shares in Thousands	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Earnings Per Share [Line Items]
Basic weighted average common shares outstanding	282,976	278,671
Weighted average common stock equivalents from assumed exercise of stock options and stock units	3,109	2,464
Incremental shares from Convertible Notes premium	5,886	2,041
Diluted weighted average common shares outstanding	291,971	283,176
Outstanding Stock Options
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	733	3,782
Restricted stock units
Weighted-average anti-dilutive shares related to:
Weighted-average anti-dilutive shares (in shares)	67	140

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 15.9	$ 12.1
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.2	2
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.4	1.9
Selling and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	2.5	2
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	8.8	6.1
Restructuring and divestiture
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 0	$ 0.1

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Stock option plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted	0.9	1
Weighted-average exercise prices	$ 39.94	$ 26.12
Share-based compensation, stock option outstanding	7.2
Weighted-average exercise price of options outstanding	$ 24.50
Unrecognized compensation expense	$ 30.7
Weighted-average period for recognition of unrecognized stock-based compensation, years	3 years 6 months
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units	0.9	1.3
Restricted stock units (RSUs), weighted average grant date fair values	$ 39.96	$ 26.17
Unvested RSUs outstanding	3.5
Unvested RSUs weighted-average grant date fair value	$ 29.36
Unrecognized compensation expense	$ 104.3
Weighted-average period for recognition of unrecognized stock-based compensation, years	2 years 7 months
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units	0.2	0.3
Restricted stock units (RSUs), weighted average grant date fair values	$ 39.96	$ 26.21
Minimum eligible percentage to receive target number of shares of company's common stock	0.00%
Maximum eligible percentage to receive target number of shares of company's common stock	200.00%
Performance stock units vesting period	3 years

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.60%	1.70%
Expected volatility	37.80%	38.60%
Expected life (in years)	4 years 8 months	5 years 3 months 3 days
Dividend yield	$ 0	$ 0
Weighted average fair value of options granted	$ 13.13	$ 9.44

Other Balance Sheet Informati56

Other Balance Sheet Information - Other Balance Sheet Information of Inventories (Detail) - USD ($) $ in Millions	Dec. 26, 2015	Sep. 26, 2015
Balance Sheet Related Disclosures [Abstract]
Raw materials	$ 103.1	$ 98.3
Work-in-process	58.7	58.7
Finished goods	124.6	126.1
Inventories	$ 286.4	$ 283.1

Other Balance Sheet Informati57

Other Balance Sheet Information - Other Balance Sheet Information of Property, Plant and Equipment (Detail) - USD ($) $ in Millions	Dec. 26, 2015	Sep. 26, 2015
Balance Sheet Related Disclosures [Abstract]
Equipment and software	$ 371.4	$ 365.9
Equipment under customer usage agreements	311.1	305.7
Building and improvements	182.5	182.1
Leasehold improvements	58.6	59.2
Land	51.4	51.4
Furniture and fixtures	17.1	17.3
Property, plant and equipment, gross	992.1	981.6
Less – accumulated depreciation and amortization	(537.6)	(524.5)
Property, plant and equipment, net	$ 454.5	$ 457.1

Business Segments and Geograp58

Business Segments and Geographic Information - Additional Information (Detail)	3 Months Ended
	Dec. 26, 2015USD ($)CustomerSegment	Dec. 27, 2014USD ($)	Sep. 26, 2015Customer
Segment Reporting Disclosure [Line Items]
Number of reportable segments | Segment	4
Revenues | $	$ 695,200,000	$ 652,800,000
Customers with balances greater than 10% of accounts receivable | Customer	0		0
Customer represented greater than 10% of consolidated revenues	0	0
Countries with greater than 10% of consolidated revenue | Customer	0
Number of reportable segments | Segment	4
Intersegment
Segment Reporting Disclosure [Line Items]
Revenues | $	$ 0	$ 0

Business Segments and Geograp59

Business Segments and Geographic Information - Segment Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Sep. 26, 2015
Segment Reporting Information [Line Items]
Total revenues	$ 695.2	$ 652.8
Operating income (loss)	126.1	103.5
Depreciation and amortization	115.9	122
Capital expenditures	19.7	21.1
Identifiable assets	7,679.5		$ 7,670.1
Diagnostics
Segment Reporting Information [Line Items]
Total revenues	310.7	304.1
Operating income (loss)	31.6	28.2
Depreciation and amortization	83.7	88.6
Capital expenditures	11.9	14.8
Identifiable assets	3,979.1		4,055.8
Breast Health
Segment Reporting Information [Line Items]
Total revenues	262.2	242
Operating income (loss)	71.6	60.6
Depreciation and amortization	7.3	7.6
Capital expenditures	2	2.6
Identifiable assets	815.3		815.4
GYN Surgical
Segment Reporting Information [Line Items]
Total revenues	98.8	84.4
Operating income (loss)	20.8	13.1
Depreciation and amortization	24.6	25.6
Capital expenditures	3.4	2
Identifiable assets	1,634.3		1,658.1
Skeletal Health
Segment Reporting Information [Line Items]
Total revenues	23.5	22.3
Operating income (loss)	2.1	1.6
Depreciation and amortization	0.3	0.2
Capital expenditures	0.1	0.2
Identifiable assets	27.3		25.3
Corporate
Segment Reporting Information [Line Items]
Capital expenditures	2.3	$ 1.5
Identifiable assets	$ 1,223.5		$ 1,115.5

Business Segments and Geograp60

Business Segments and Geographic Information - Revenues by Geography (Detail)	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Schedule Of Geographical Segments [Line Items]
Revenues	100.00%	100.00%
United States
Schedule Of Geographical Segments [Line Items]
Revenues	78.40%	74.00%
Europe
Schedule Of Geographical Segments [Line Items]
Revenues	10.00%	13.60%
Asia-Pacific
Schedule Of Geographical Segments [Line Items]
Revenues	7.90%	8.70%
All others
Schedule Of Geographical Segments [Line Items]
Revenues	3.70%	3.70%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Income Tax Disclosure [Abstract]
Company's effective tax rate	25.90%	33.80%

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 26, 2015	Sep. 26, 2015
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 5,321.8	$ 5,322.8
Accumulated Amortization	2,395.1	2,299.6
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3,979	3,979.1
Accumulated Amortization	1,771.8	1,698.5
In-process research and development
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	3.7	3.7
Accumulated Amortization	0	0
Customer relationships and contracts
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	1,100.3	1,101.1
Accumulated Amortization	487.2	467.5
Trade names
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	236.3	236.4
Accumulated Amortization	134	131.5
Business licenses
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	2.5	2.5
Accumulated Amortization	$ 2.1	$ 2.1

Intangible Assets - Schedule 63

Intangible Assets - Schedule of Estimated Amortization Expense (Detail) $ in Millions	Dec. 26, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of Fiscal 2016	$ 280.7
Fiscal 2,017	365.2
Fiscal 2,018	354.7
Fiscal 2,019	343
Fiscal 2,020	$ 332

Product Warranties - Product Wa

Product Warranties - Product Warranty (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance at Beginning of Period	$ 5.4	$ 6.3
Provisions	5.7	1.5
Settlements/ Adjustments	(1.7)	(1.8)
Balance at End of Period	$ 9.4	$ 6

Product Warranties Additional I

Product Warranties Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014
Product Warranty Liability [Line Items]
Provisions	$ 5.7	$ 1.5
CHINA
Product Warranty Liability [Line Items]
Provisions	$ 4

Accumuated Other Comprehensiv66

Accumuated Other Comprehensive Income Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Millions	3 Months Ended
	Dec. 26, 2015	Dec. 27, 2014	Sep. 26, 2015	Sep. 27, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Changes in foreign currency translation adjustment	$ (4.2)	$ (9)
Changes in unrealized holding gains and losses on available-for-sale securities:	(0.6)	5.1
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	0	(0.1)
Changes in value of hedged interest rate caps, net of tax of $0.2:	0.3	0
Other Comprehensive Income (Loss) before Reclassifications, Tax	(4.5)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(11.4)	(3.8)
Restructuring Reserve, Translation and Other Adjustment	(6.9)	0
Accumulated other comprehensive loss	(25.9)	(1.2)	$ (14.5)	$ 2.6
Foreign Currency Translation
Accumulated Other Comprehensive Income (Loss) [Line Items]
Changes in foreign currency translation adjustment	(4.2)
Restructuring Reserve, Translation and Other Adjustment	0	0
Accumulated other comprehensive loss	(19.9)	(13.7)	(15.7)	(4.7)
Equity securities
Accumulated Other Comprehensive Income (Loss) [Line Items]
Changes in unrealized holding gains and losses on available-for-sale securities:	(0.6)
Restructuring Reserve, Translation and Other Adjustment	(7.2)	0
Accumulated other comprehensive loss	(0.9)	14	6.9	8.9
Pension in Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	0
Restructuring Reserve, Translation and Other Adjustment	0	0
Accumulated other comprehensive loss	(1.8)	$ (1.5)	(1.8)	$ (1.6)
Interest rate cap - derivative
Accumulated Other Comprehensive Income (Loss) [Line Items]
Changes in value of hedged interest rate caps, net of tax of $0.2:	0.3
Restructuring Reserve, Translation and Other Adjustment	0.3
Accumulated other comprehensive loss	$ (3.3)		$ (3.9)